Ventria Bioscience and EMD Millipore Announce Exclusive Global Supply and Marketing Agreement

FORT COLLINS, Colo. – March 21, 2012 – Ventria Bioscience today announced an exclusive collaboration with EMD Millipore, the Life Science division of Merck KGaA of Germany, in which Ventria will manufacture and supply a recombinant protein to EMD Millipore. EMD Millipore will exclusively market and distribute this product, manufactured using Ventria's ExpressTec system, to its customers on a global basis.

"Ventria's ExpressTec biomanufacturing system provides a highly efficient source of non-animal origin recombinant products derived from plants," said Morgan Norris, Head of Biopharm Materials and Technologies, EMD Millipore. "These products offer EMD Millipore the opportunity to expand its CellPrime™ line of non-animal origin products and provide customers with a wide range of solutions for biomanufacturing."

ExpressTec enables large-scale, cost-effective production of high-quality recombinant protein and peptide products used as biotherapeutics, vaccines and as part of the biomanufacturing process. The recombinant material will be completely free of animal- or human-derived components, and meet EMD Millipore's requirements for use in cGMP biomanufacturing.

"This collaboration with EMD Millipore, an industry leader in biomanufacturing, aligns Ventria's recombinant protein manufacturing technology with EMD Millipore's technical applications expertise and customer relationships in research, development and bioproduction," said Randy Semadeni, Vice President Business Development for Ventria Bioscience. "We look forward to working with EMD Millipore on this and future endeavors to expand our offering of high quality animal component-free recombinant proteins."

About Ventria Bioscience
Ventria Bioscience develops, manufactures and markets biotherapeutics, vaccines and products used in bioprocessing, regenerative medicine, cell culture media, and research and development. Ventria's patented ExpressTec biomanufacturing technology enables the development of new and cost-effective biologic products. For more information visit www.Ventria.com.

About EMD Millipore
EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science.

Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 67 countries and 2010 revenues of $2.2 billion. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.